Search

Your search keyword '"Renaud, Thomas"' showing total 234 results
Start Over Author "Renaud, Thomas"
234 results on '"Renaud, Thomas"'

2. Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model

Author

Willemin, Marie-Emilie, Gong, Jue, Hilder, Brandi W., Masterson, Tara, Tolbert, Jaszianne, Renaud, Thomas, Heuck, Christoph, Kane, Colleen, De Zwart, Loeckie, Girgis, Suzette, Ma, Xuewen, and Ouellet, Daniele

Published
2024
Full Text
View/download PDF

4. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.

Author

Rodriguez-Otero, Paula, van de Donk, Niels, Pillarisetti, Kodandaram, Cornax, Ingrid, Vishwamitra, Deeksha, Gray, Kathleen, Hilder, Brandi, Tolbert, Jaszianne, Renaud, Thomas, Masterson, Tara, Heuck, Christoph, Kane, Colleen, Verona, Raluca, Moreau, Philippe, Bahlis, Nizar, and Chari, Ajai

Subjects
Humans, Multiple Myeloma, Receptors, Chimeric Antigen, Antibodies, Bispecific, Neoplasm Recurrence, Local, Immunotherapy, Adoptive, Receptors, G-Protein-Coupled
Abstract

Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Despite advances in therapy, patients experience cycles of remission and relapse, with each successive line of therapy associated with poorer outcomes; therefore, therapies with different mechanisms of action against new myeloma antigens are needed. G protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a novel therapeutic target for the treatment of multiple myeloma. We review the biology and target validation of GPRC5D, and clinical data from early phase trials of GPRC5D-targeting bispecific antibodies, talquetamab and forimtamig, and chimeric antigen receptor T cell (CAR-T) therapies, MCARH109, OriCAR-017, and BMS-986393. In addition to adverse events (AEs) associated with T-cell-redirection therapies irrespective of target, a consistent pattern of dermatologic and oral AEs has been reported across several trials of GPRC5D-targeting bispecific antibodies, as well as rare cerebellar events with CAR-T therapy. Additional studies are needed to understand the underlying mechanisms involved in the development of skin- and oral-related toxicities. We review the strategies that have been used to manage these GPRC5D-related toxicities. Preliminary efficacy data showed overall response rates for GPRC5D-targeting T-cell-redirecting therapies were ≥64%; most responders achieved a very good partial response or better. Pharmacokinetics/pharmacodynamics showed that these therapies led to cytokine release and T-cell activation. In conclusion, results from early phase trials of GPRC5D-targeting T-cell-redirecting agents have shown promising efficacy and manageable safety profiles, including lower infection rates compared with B-cell maturation antigen- and Fc receptor-like protein 5-targeting bispecific antibodies. Further clinical trials, including those investigating GPRC5D-targeting T-cell-redirecting agents in combination with other anti-myeloma therapies and with different treatment modalities, may help to elucidate the future optimal treatment regimen and sequence for patients with multiple myeloma and improve survival outcomes. Video Summary.

Published
2024

6. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

Author

Einsele, Hermann, Moreau, Philippe, Bahlis, Nizar, Bhutani, Manisha, Vincent, Laure, Karlin, Lionel, Perrot, Aurore, Goldschmidt, Hartmut, van de Donk, Niels W. C. J., Ocio, Enrique M., Martinez-Lopez, Joaquin, Rodríguez-Otero, Paula, Dytfeld, Dominik, Diels, Joris, Strulev, Vadim, Haddad, Imene, Renaud, Thomas, Ammann, Eric, Cabrieto, Jedelyn, Perualila, Nolen, Gan, Ryan, Zhang, Youyi, Parekh, Trilok, Albrecht, Claire, Weisel, Katja, and Mateos, Maria-Victoria

Published
2024
Full Text
View/download PDF

12. Validation of an immersed boundary method for compressible flows

Author

Renaud, Thomas, Benoit, Christophe, Péron, Stephanie, Mary, Ivan, and Alferez, Nicolas

Subjects
Physics - Fluid Dynamics, Physics - Computational Physics
Abstract

This paper sums up some recent validations of an immersed boundary method for compressible flow simulations. It has been already shown that this method is able to provide accurate results without meshing effort around more or less complex geometries. Here, the authors focus on several simple test cases to assess the application range of the method. From subsonic to hypersonic flows, from steady to large-eddy unsteady simulations, in 2D or 3D, results are compared to classical simulations with body-fitted meshes and experiment. Moreover, the use of an efficient Navier-Stokes solver for all the cases is part of the benefit of the approach to provide a CFD solution in a reduced time.

Published
2019

17. P-328 Talquetamab vs real-world physician's choice of therapy (RWPC): comparative efficacy in patients (pts) with triple-class exposed (TCE) relapsed/ refractory multiple myeloma (RRMM)

Author

Ye, Jing Christine, primary, Biran, Noa, additional, Nair, Sandhya, additional, Lin, Xiwu, additional, Qi, Keqin, additional, Londhe, Anil, additional, Ammann, Eric, additional, Renaud, Thomas, additional, Kane, Colleen, additional, Parekh, Trilok, additional, Gray, Kathleen, additional, Peterson, Steve, additional, and Costa, Luciano, additional

Published
2023
Full Text
View/download PDF

18. MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

Author

Rodriguez-Otero, Paula, primary, Schinke, Carolina, additional, Chari, Ajai, additional, Lipe, Brea, additional, Lavi, Noa, additional, Rasche, Leo, additional, Vishwamitra, Deeksha, additional, Skerget, Sheri, additional, Verona, Raluca, additional, Ma, Xuewen, additional, Khedkar, Sheetal, additional, Hilder, Brandi, additional, Masterson, Tara, additional, Campagna, Michela, additional, Renaud, Thomas, additional, Tolbert, Jaszianne, additional, Heuck, Christoph, additional, Smit, M Damiette, additional, and van de Donk, Niels, additional

Published
2023
Full Text
View/download PDF

19. POSTER: MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

Author

Rodriguez-Otero, Paula, primary, Schinke, Carolina, additional, Chari, Ajai, additional, Lipe, Brea, additional, Lavi, Noa, additional, Rasche, Leo, additional, Vishwamitra, Deeksha, additional, Skerget, Sheri, additional, Verona, Raluca, additional, Ma, Xuewen, additional, Khedkar, Sheetal, additional, Hilder, Brandi, additional, Masterson, Tara, additional, Campagna, Michela, additional, Renaud, Thomas, additional, Tolbert, Jaszianne, additional, Heuck, Christoph, additional, Smit, M Damiette, additional, and van de Donk, Niels, additional

Published
2023
Full Text
View/download PDF

20. P-023 Talquetamab, a G protein–coupled receptor family C group 5 member D × CD3 bispecific antibody, in relapsed/refractory multiple myeloma: efficacy and safety of patient subgroups from monumenTAL-1

Author

Krishnan, Amrita, primary, Costa, Luciano, additional, Schinke, Carolina, additional, Karlin, Lionel, additional, Morillo, Daniel, additional, Martinez-Chamorro, Carmen, additional, Ye, Jing Christine, additional, Chari, Ajai, additional, Moreau, Philippe, additional, Caers, Jo, additional, Jakubowiak, Andrzej, additional, Campagna, Michela, additional, Masterson, Tara, additional, Hilder, Brandi, additional, Tolbert, Jaszianne, additional, Renaud, Thomas, additional, Smit, M. Damiette, additional, Heuck, Christoph, additional, and Minnema, Monique, additional

Published
2023
Full Text
View/download PDF

21. P893: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS

Author

Oriol, Albert, primary, Qi, Keqin, additional, Londhe, Anil, additional, Nair, Sandhya, additional, Lin, Xiwu, additional, Pei, Lixia, additional, Ammann, Eric, additional, Heuck, Christoph, additional, Renaud, Thomas, additional, Kane, Colleen, additional, Parekh, Trilok, additional, and Peterson, Steve, additional

Published
2023
Full Text
View/download PDF

22. S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Author

Touzeau, Cyrille, primary, Schinke, Carolina, additional, Minnema, Monique, additional, van de Donk, Niels W.C.J., additional, Rodríguez-Otero, Paula, additional, Mateos, Maria-Victoria, additional, Rasche, Leo, additional, Ye, Jing Christine, additional, Vishwamitra, Deeksha, additional, MA, Xuewen, additional, Qin, Xiang, additional, Campagna, Michela, additional, Masterson, Tara, additional, Hilder, Brandi, additional, Tolbert, Jaszianne, additional, Renaud, Thomas, additional, Goldberg, Jenna, additional, Heuck, Christoph, additional, and Chari, Ajai, additional

Published
2023
Full Text
View/download PDF

23. P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Einsele, Hermann, primary, Moreau, Philippe, additional, Bahlis, Nizar J, additional, Bhutani, Manisha, additional, Vincent, Laure, additional, Karlin, Lionel, additional, Perrot, Aurore, additional, Goldschmidt, Hartmut, additional, van de Donk, Niels W.C.J., additional, Ocio, Enrique, additional, Martinez-Lopez, Joaquín, additional, Rodríguez-Otero, Paula, additional, Dytfeld, Dominik, additional, Diels, Joris, additional, Strulev, Vadim, additional, Haddad, Imene, additional, Renaud, Thomas, additional, Ammann, Eric, additional, Cabrieto, Jedelyn, additional, Perualila, Nolen, additional, Gan, Ryan, additional, Zhang, Youyi, additional, Parekh, Trilok, additional, Albrecht, Claire, additional, Weisel, Katja, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

24. P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1

Author

Rasche, Leo, primary, Schinke, Carolina, additional, Chari, Ajai, additional, Lipe, Brea C., additional, Lavi, Noa, additional, Rodríguez-Otero, Paula, additional, Vishwamitra, Deeksha, additional, Skerget, Sheri, additional, Verona, Raluca, additional, MA, Xuewen, additional, Khedkar, Sheetal, additional, Hilder, Brandi, additional, Masterson, Tara, additional, Campagna, Michela, additional, Renaud, Thomas, additional, Tolbert, Jaszianne, additional, Heuck, Christoph, additional, Smit, Damiette, additional, and van de Donk, Niels W.C.J., additional

Published
2023
Full Text
View/download PDF

25. PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Ye, Jing Christine, primary, Biran, Noa, additional, Nair, Sandhya, additional, Lin, Xiwu, additional, Qi, Keqin, additional, Londhe, Anil, additional, Ammann, Eric, additional, Renaud, Thomas, additional, Kane, Colleen, additional, Parekh, Trilok, additional, Gray, Kathleen, additional, Peterson, Steve, additional, and Costa, Luciano, additional

Published
2023
Full Text
View/download PDF

30. Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Author

Touzeau, Cyrille, primary, Chari, Ajai, additional, Schinke, Carolina, additional, Minnema, Monique C., additional, Berdeja, Jesus, additional, Oriol, Albert, additional, Van De Donk, Niels WCJ, additional, Rodriguez Otero, Paula, additional, Askari, Elham, additional, Mateos, Maria-Victoria, additional, Costa, Luciano J., additional, Caers, Jo, additional, Rasche, Leo, additional, Krishnan, Amrita Y., additional, Vishwamitra, Deeksha, additional, Ma, Xuewen, additional, Qin, Xiang, additional, Gries, Katharine S., additional, Kato, Kelly, additional, Campagna, Michela, additional, Masterson, Tara, additional, Hilder, Brandi, additional, Tolbert, Jaszianne, additional, Renaud, Thomas, additional, Goldberg, Jenna D., additional, Heuck, Chris, additional, Moreau, Philippe, additional, and San-Miguel, Jesús, additional

Published
2022
Full Text
View/download PDF

31. Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Author

Chari, Ajai, primary, Touzeau, Cyrille, additional, Schinke, Carolina, additional, Minnema, Monique C., additional, Berdeja, Jesus, additional, Oriol, Albert, additional, Van De Donk, Niels WCJ, additional, Rodriguez Otero, Paula, additional, Askari, Elham, additional, Mateos, Maria-Victoria, additional, Costa, Luciano J., additional, Caers, Jo, additional, Rasche, Leo, additional, Krishnan, Amrita Y., additional, Vishwamitra, Deeksha, additional, Ma, Xuewen, additional, Qin, Xiang, additional, Gries, Katharine S., additional, Campagna, Michela, additional, Masterson, Tara, additional, Hilder, Brandi, additional, Tolbert, Jaszianne, additional, Renaud, Thomas, additional, Goldberg, Jenna D., additional, Heuck, Christoph, additional, San-Miguel, Jesús, additional, and Moreau, Philippe, additional

Published
2022
Full Text
View/download PDF

32. MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Rasche, Leo, Schinke, Carolina, Touzeau, Cyrille, Minnema, Monique C., van de Donk, Niels W.C.J., Rodríguez-Otero, Paula, Mateos, María-Victoria, Christine Ye, Jing, Vishwamitra, Deeksha, Singh, Indrajeet, Qin, Xiang, Campagna, Michela, Masterson, Tara, Hilder, Brandi W., Tolbert, Jaszianne, Renaud, Thomas, Heuck, Christoph, Kane, Colleen, and Chari, Ajai

Published
2024
Full Text
View/download PDF

33. MM-349 Talquetamab (Tal), a GPRC5D×CD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study

Author

Searle, Emma, Quach, Hang, Biran, Noa, Perrot, Aurore, Berdeja, Jesus G, Dorritie, Kathleen, Van Elssen, Catharina, Touzeau, Cyrille, Anguille, Sébastien, Vishwamitra, Deeksha, Nguyen, Ashley, Ghosh, Debopriya, Shearin, Elizabeth, Mason, Gary E, Renaud, Thomas, and Matous, Jeffrey

Published
2024
Full Text
View/download PDF

34. Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Rasche, Leo, Schinke, Carolina, Touzeau, Cyrille, Minnema, Monique C., van de Donk, Niels W.C.J., Rodríguez-Otero, Paula, Mateos, María-Victoria, Christine Ye, Jing, Vishwamitra, Deeksha, Singh, Indrajeet, Qin, Xiang, Campagna, Michela, Masterson, Tara, Hilder, Brandi W., Tolbert, Jaszianne, Renaud, Thomas, Heuck, Christoph, Kane, Colleen, and Chari, Ajai

Published
2024
Full Text
View/download PDF

35. Talquetamab (Tal), a GPRC5D×CD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study

Author

Searle, Emma, Quach, Hang, Biran, Noa, Perrot, Aurore, Berdeja, Jesus G, Dorritie, Kathleen, Van Elssen, Catharina, Touzeau, Cyrille, Anguille, Sébastien, Vishwamitra, Deeksha, Nguyen, Ashley, Ghosh, Debopriya, Shearin, Elizabeth, Mason, Gary E, Renaud, Thomas, and Matous, Jeffrey

Published
2024
Full Text
View/download PDF

36. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.

Author

Lipe, Brea C and Renaud, Thomas

Subjects
*INTERLEUKINS, *TOCILIZUMAB, *MONOCLONAL antibodies, *CYTOKINE release syndrome, *PRIMARY health care, *MULTIPLE myeloma, *IMMUNOTHERAPY
Abstract

Introduction: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common toxicities associated with immunotherapies, including T cell redirecting bispecific antibodies. Although cooperative group guidelines recommend the use of tocilizumab or other IL-6/IL-6R inhibitors for the management of CRS and ICANS, reports on the use of siltuximab, an IL-6 inhibitor, for the treatment of CRS are limited. Case report: We present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab. Management and Outcome: The patient received an infusion of siltuximab. The patient recovered from CRS within 1 h of siltuximab administration and ICANS within 7 h of siltuximab administration. Patient tolerated the subsequent dose of talquetamab with no evidence of CRS and continued on study. Discussion: This case describes the successful use of siltuximab for the management of CRS in a patient treated with a T cell redirecting bispecific antibody for RRMM. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. sj-pdf-1-hsr-10.1177_13558196211065704 ��� Supplemental material for An evaluation of five regional health information technology-based programmes to improve health and social care coordination: A quasi-experimental controlled before/after mixed design

Author

Salmi, Louis-Rachid, Roberts, Tamara, Renaud, Thomas, Buffeteau, Sophie, Cueille, Sandrine, Fourneyron, Emmanuelle, Gaillard, Aur��lie, Abraham, Maelys, Arditi, Nora, Castry, Mathieu, Daniel, Fabien, N'gom, N'deye Fatou, Gu��ry, Orlane, L'Horty, Yannick, Pincemail, St��phane, Purgues, Sonia, Thiessard, Franz, Ramel, Viviane, Langlois, Emmanuel, Saillour-Gl��nisson, Florence, Sib��, Matthieu, and Wittwer, J��r��me

Subjects
111708 Health and Community Services, 111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences
Abstract

Supplemental material, sj-pdf-1-hsr-10.1177_13558196211065704 for An evaluation of five regional health information technology-based programmes to improve health and social care coordination: A quasi-experimental controlled before/after mixed design by Louis-Rachid Salmi, Tamara Roberts, Thomas Renaud, Sophie Buffeteau, Sandrine Cueille, Emmanuelle Fourneyron, Aur��lie Gaillard, Maelys Abraham, Nora Arditi, Mathieu Castry, Fabien Daniel, N'deye Fatou N'gom, Orlane Gu��ry, Yannick L'Horty, St��phane Pincemail, Sonia Purgues, Franz Thiessard, Viviane Ramel, Emmanuel Langlois, Florence Saillour-Gl��nisson, Matthieu Sib�� and J��r��me Wittwer in Journal of Health Services Research & Policy

Published
2022
Full Text
View/download PDF

43. Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Author

Jakubowiak, Andrzej J, Anguille, Sebastien, Karlin, Lionel, Chari, Ajai, Schinke, Carolina, Rasche, Leo, San-Miguel, Jesus, Campagna, Michela, Hilder, Brandi W, Masterson, Tara J, Qin, Xiang, Renaud, Thomas, Tolbert, Jaszianne, Vishwamitra, Deeksha, Skerget, Sheri, and Moreau, Philippe

Published
2023
Full Text
View/download PDF

45. Cartesian CFD Methods for Complex Applications

Author

Peron, Stephanie, Renaud, Thomas, Christophe, Benoit, mary, ivan, DAAA, ONERA, Université Paris-Saclay [Châtillon], and ONERA-Université Paris-Saclay

Subjects
Physics::Fluid Dynamics, MODÈLE DE PAROI, [PHYS]Physics [physics], MAILLAGE ADAPTATIF, [SPI]Engineering Sciences [physics], [CHIM]Chemical Sciences, [INFO]Computer Science [cs], METHODE FRONTIERE IMMERGEE, [MATH]Mathematics [math], MAILLAGE CARTESIEN
Abstract

International audience; This paper presents an Immersed Boundary Method for the simulation of compressible turbulent flows on adaptive Cartesian grids. This method relies on a "Ghost Cells" direct forcing approach, which consists in a reconstruction of the solution at some particular points in the vicinity of the obstacles (which are not a border of the mesh). Because of the isotropy of Cartesian cells, which leads to a prohibitive cell count to simulate the boundary layer by the mesh, a wall model is applied at these forced points, reducing significantly the number of points. In this paper, this method is described and its implementation with the Cassiopee/Fast environment developed at ONERA. Two applications are considered: the first application is a steady turbulent simulation of the flow around a tripod mounted in a wind tunnel. This assesses the capability of the method to perform accurate and robust simulations around complex geometries without the mesh generation effort usually required by body-fitted approaches. This application demonstrates also that the present immersed boundary method models not only wall boundaries but also other kind of boundary conditions, such as injection and outlet imposed pressure boundary conditions. The second application which is considered is an unsteady simulation of the flow around a high-lift three-element airfoil. The aim of this test-case is to demonstrate that the method enables to capture the aerodynamics of such unsteady complex flows.

Published
2021

47. L'enquête SHARE : une enquête longitudinale sur la santé, la retraite et le vieillissement en Europe

Author

Renaud, Thomas, Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL), Laboratoire d'Economie de Dauphine (LEDa), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Laboratoire d'Economie et de Gestion des Organisations de Santé (Legos), Laboratoire d'Economie et de Gestion des Organisations de Santé de l’Université Paris-Dauphine (LEDa-LEGOS), Plateforme universitaire de données de Nanterre - MSH-Mondes, and Chauvel, Brian

Subjects
Europe, Santé, [SHS.DEMO] Humanities and Social Sciences/Demography, 50+, [SHS] Humanities and Social Sciences, [SHS.DEMO]Humanities and Social Sciences/Demography, Vieillissement, Retraite, Données d'enquêtes, [SHS]Humanities and Social Sciences
Abstract

National audience; Présentation publique de l’enquête européenne SHARE (Survey on Health, Ageing and Retirement in Europe) : une enquête longitudinale, multidisciplinaire et internationale concernant plus de 80 000 européens âgés de 50 ans et plus. L’enquête est réalisée tous les deux ans depuis 2004 et se déroule désormais dans vingt-sept pays européens. Les données recueillies grâce à SHARE portent sur l'état de santé des répondants et de leurs proches ainsi que sur leur situation sociale (famille, entraide, réseaux sociaux) et économique (emploi, retraite, patrimoine). Les données de SHARE sont gratuites et mises à disposition des chercheurs qui en formulent la demande

Published
2020

49. Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

Author

Plesner, Torben, primary, Dimopoulos, Meletios A., additional, Oriol, Albert, additional, San‐Miguel, Jesus, additional, Bahlis, Nizar J., additional, Rabin, Neil, additional, Suzuki, Kenshi, additional, Yoon, Sung‐Soo, additional, Ben‐Yehuda, Dina, additional, Cook, Gordon, additional, Goldschmidt, Hartmut, additional, Grosicki, Sebastian, additional, Qin, Xiang, additional, Fastenau, John, additional, Garvin, Wendy, additional, Carson, Robin, additional, Renaud, Thomas, additional, and Gries, Katharine S., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results